Robinson M K, Sozeri T J
Health & Personal Care Technology Division, Procter & Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio 45239.
J Invest Dermatol. 1990 Nov;95(5):587-91. doi: 10.1111/1523-1747.ep12505576.
The clonidine transdermal therapeutic system (clonidine-TTS) has been associated with a significant incidence of allergic contact sensitization. This incidence was not predicted by premarket skin sensitization testing in animals or humans. One possible explanation lies in recent findings in guinea pigs that clonidine exposure could inhibit the elicitation of skin reactions to unrelated strong contact sensitizers. However, these studies also showed that clonidine pretreatment did not appear to affect the induction of contact sensitization. On this basis, we sought to specifically evaluate the induction phase of sensitization to clonidine as an alternative means of assessing its sensitization properties. The method selected was the assay of in situ lymphocyte proliferation in lymph nodes draining the sites of clonidine exposure, a method recently promoted as an alternative means to assess contact allergenic potential. Utilizing various induction application techniques and regimens, we were consistently unable to demonstrate clonidine's allergenic potential through such an assessment of lymphocyte proliferation. We were also unable to demonstrate sensitization by in vivo ear swelling or in vitro lymphocyte blastogenesis assay techniques. However, a subsequent assessment of the effect of clonidine exposure on the induction of sensitization to unrelated strong contact allergens demonstrated a consistent 40-70% inhibition of the proliferative response to the contact allergens oxazolone and trinitrochlorobenzene. This was similar to the degree of suppression produced by the corticosteroids fluocinonide and hydrocortisone when they were tested at 80 and 10 times lower concentrations. In addition, we observed a comparable inhibition of the ear swelling response to oxazolone. These data extend our knowledge of the immunomodulatory effects of clonidine and offer additional mechanistic insights into the failure of short-term predictive patch-test methods to detect this chemical's potential to induce allergic contact sensitization.
可乐定透皮治疗系统(可乐定-TTS)与过敏性接触致敏的发生率显著相关。这种发生率在动物或人体的上市前皮肤致敏试验中并未被预测到。一种可能的解释在于最近在豚鼠身上的发现,即接触可乐定可能会抑制对无关强接触致敏剂的皮肤反应激发。然而,这些研究也表明,可乐定预处理似乎并未影响接触致敏的诱导。在此基础上,我们试图专门评估对可乐定致敏的诱导阶段,作为评估其致敏特性的另一种方法。所选择的方法是检测可乐定接触部位引流淋巴结中的原位淋巴细胞增殖,这是一种最近被推广为评估接触致敏潜力的替代方法。利用各种诱导应用技术和方案,通过这种淋巴细胞增殖评估,我们始终无法证明可乐定的致敏潜力。我们也无法通过体内耳部肿胀或体外淋巴细胞增殖试验技术证明致敏。然而,随后对可乐定接触对无关强接触变应原致敏诱导的影响进行的评估表明,对接触变应原恶唑酮和三硝基氯苯的增殖反应持续受到40%-70%的抑制。这与氟轻松和氢化可的松等皮质类固醇在低80倍和10倍浓度下测试时产生的抑制程度相似。此外,我们观察到对恶唑酮的耳部肿胀反应也有类似的抑制作用。这些数据扩展了我们对可乐定免疫调节作用的认识,并为短期预测性斑贴试验方法未能检测到这种化学物质诱导过敏性接触致敏潜力提供了更多的机制性见解。